Premium ingredient

Clinically tested

NEW CLINICAL RESULTS

# ID-alG™

## Calorie reduction & well being

- **Fat & carb blocker**
- **Body shape improvement**
- **Weight-loss clinical studies**
- **Brown seaweed extract**

nexira HEALTH

# ID-alG™

# Weight-loss alternative for women and more specifically for 45 years & over

## Fat & carb blocker(1)

ID-alG™ is a brown seaweed extract derived from *Ascophyllum nodosum* rich in long chain polyphenols called phlorotannins which inhibit the activity of the two main digestive enzymes(1):

- Lipase inhibition activity: up to 63%
- Amylase inhibition activity: up to 77%

## Demonstrated clinical results(2)

The latest clinical results highlighted unique weight management benefits of ID-alG™ for overweight women & more specifically for 45 years & over.

- Weight-loss closely correlated with fat mass
- Decreases fat assimilation lowering body fat mass and abdominal & visceral fat (see MRI)
- Decreases carbs assimilation lowering glycated hemoglobin index Hb1Ac
- Significant and lasting effect as early as 8 weeks after initial consumption
- Improves body shape

| Significant circumference variation (16 weeks) | BMI>25 | BMI>25 45+ |
|---|---|---|
| Waist circumference (cm) | **-3.0** | **-2.7** |
| Hip circumference (cm) | **-3.0** | **-2.9** |
| Thigh circumference (cm) | **-1.7** | **-1.3** |

## Consumers' satisfaction(3)

Preliminary clinical study questionnaires assessing the satisfaction of users:

- **76%** believe ID-alG™ induces weight-loss
- **72%** would continue using ID-alG™
- **72%** would buy ID-alG™

**BODY COMPOSITION 16 WEEKS (KG)**




**FAT MASS DECREASE**







MRI: Magnetic Resonance Imaging

## NATURAL WEIGHT MANAGEMENT INGREDIENT

- **Supported by clinical, published *in vivo* studies**
- **Guaranteed enzyme inhibition (≥ 50%)**
- **Guaranteed iodine content below RDI with 200 mg ID-alG™ twice daily (before main meals)(4)**


(1) *In tubo* test of the inhibition properties of ID-alG™ on pancreatic lipase and bacterial amylase.
(2) Bicentric, randomized, placebo-controlled, in parallel double blind format study, run in 2014-2015 on 88 women using 200 mg ID-alG™ twice daily during 16 weeks.
(3) Evaluation of ID-alG™'s weight management effect on overweight women. Monocentric, randomized, placebo controlled clinical study run in March 2010, on 56 women using 400 mg of ID-alG™ daily for 8 weeks.
(4) Iodine Recommended Daily Intake = 150 µg/day according to regulations (EC) n°1169/2011 & (US) 21 CFR101.9

NEXIRA - www.nexira.com • France (Headquarters) +33 2 32 831818 • USA +1 908 7079400 • Brazil +55 11 3803 7373 • Japan: +81 3 6809 1380
Mexico: +52 55 55 36 83 83 • China (Shanghai): +86 21 6132 7186 • China (Guangzhou): +86 20 3830 3074 • India: +91 22 6507 0700



nexira HEALTH

Ref.170330 - Ind4